IGC Pharma, Inc. (NASDAQ:IGC) | WebDisclosure

Basculer en Français

9840	Companies
197563	Keywords
128649	Articles
105078	Press releases

Home
Companies
IGC Pharma, Inc.

PRESS RELEASE

published on 11/14/2024 at 14:30, 1 year 2 months ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
IGC Pharma, Inc. announces Q2 FY2025 financial results and strategic advancements including breakthroughs in Alzheimer's treatment pipeline. Revenue grows 42% to $412k. R&D expenses decrease 28%

Financial Results R&D Expenses Q2 FY2025 IGC Pharma Alzheimer's Treatment
BRIEF

published on 11/06/2024 at 14:35, 1 year 3 months ago

IGC Pharma met en avant des avancées stratégiques dans les thérapies contre la maladie d'Alzheimer et la perte de poids

Intelligence Artificielle Perte De Poids Agonistes Du GLP-1 IGC Pharma Traitement De La Maladie D'Alzheimer
BRIEF

published on 11/06/2024 at 14:35, 1 year 3 months ago

IGC Pharma Highlights Strategic Advances in Alzheimer's and Weight Loss Therapies

Weight Loss Artificial Intelligence GLP-1 Agonists IGC Pharma Alzheimer's Treatment
PRESS RELEASE

published on 11/06/2024 at 14:30, 1 year 3 months ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
IGC Pharma, Inc. (NYSE American: IGC) announces a new interview with CEO Ram Mukunda discussing strategic expansion into metabolic and neurological markets, focusing on Alzheimer's and weight loss therapies, leveraging AI for diverse pipeline

Interview Neurodegenerative Disorders Metabolic Disorders IGC Pharma Ram Mukunda
BRIEF

published on 10/17/2024 at 14:35, 1 year 3 months ago

IGC Pharma étend son essai sur la maladie d'Alzheimer au Canada grâce à un partenariat avec Baycrest

IGC Pharma IGC-AD1 Essai Sur La Maladie D'Alzheimer Partenariat Baycrest Phase 2 Clinique
BRIEF

published on 10/17/2024 at 14:35, 1 year 3 months ago

IGC Pharma Expands Alzheimer's Trial to Canada with Baycrest Partnership

IGC Pharma Alzheimer's Trial IGC-AD1 Baycrest Partnership Phase 2 Clinical
PRESS RELEASE

published on 10/17/2024 at 14:30, 1 year 3 months ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
IGC Pharma expands Phase 2 trial to Canada at Baycrest Academy for Research and Education in Toronto, Ontario, to investigate IGC-AD1 for treating agitation in Alzheimer's dementia

Phase 2 Trial Alzheimer's IGC Pharma Agitation Treatment Baycrest Academy
BRIEF

published on 10/03/2024 at 15:05, 1 year 4 months ago

IGC Pharma Secures Two Awards in NIH's AI PREPARE Challenge

AI Technology Healthcare Innovation IGC Pharma Alzheimer's Prediction NIH Challenge
BRIEF

published on 10/03/2024 at 15:05, 1 year 4 months ago

IGC Pharma remporte deux prix lors du concours AI PREPARE Challenge du NIH

Technologie De L'IA Innovation Dans Le Domaine De La Santé IGC Pharma Prédiction De La Maladie D'Alzheimer Défi Du NIH
PRESS RELEASE

published on 10/03/2024 at 15:00, 1 year 4 months ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
IGC Pharma, Inc. wins 2 awards in the PREPARE Challenge for Alzheimer's research with its MHAS entry. Recognition highlights leadership in AI for disease prediction

Artificial Intelligence Healthcare Innovation Alzheimer's Research IGC Pharma PREPARE Challenge

Accesswire

Published on 02/11/2026 at 01:00, 18 minutes ago

Kidoz Inc. Appoints John Nolie as Vice President of Sales, North America
Published on 02/10/2026 at 22:50, 2 hours 28 minutes ago

Tectonic Metals Announces Financing of up to $40 Million
Published on 02/10/2026 at 22:15, 3 hours 3 minutes ago

Earthwise Minerals Completes Private Placement and Makes Changes to the Management Team
Published on 02/10/2026 at 15:30, 9 hours 48 minutes ago

Predictiv AI Establishes Asia Regional Office to Support Expansion Across Asia, Africa, and the Middle East
Published on 02/10/2026 at 15:00, 10 hours 18 minutes ago

Haven Safety AI Launches AI-Native Safety Intelligence Platform Co-Founded with The AES Corporation and AI Fund

View all ACCESSWIRE

EQS Group

Published on 02/10/2026 at 23:33, 1 hour 45 minutes ago

EQS-Adhoc: All for One Group SE: resolves on a public share buyback offer for up to 2.3% of the share capital and proposes to the Annual General Meeting an amended appropriation of retained earnings
Published on 02/10/2026 at 22:51, 2 hours 27 minutes ago

Gerresheimer AG reschedules publication of annual and consolidated financial statements for 2025 and initiates sale of Centor Inc.
Published on 02/10/2026 at 22:28, 2 hours 50 minutes ago

EQS-Adhoc: Gerresheimer AG reschedules publication of annual and consolidated financial statements for 2025 and initiates sale of Centor Inc.
Published on 02/10/2026 at 19:07, 6 hours 11 minutes ago

Wacker Neuson Group publishes preliminary financial year 2025 figures and shows a positive outlook
Published on 02/10/2026 at 19:06, 6 hours 12 minutes ago

EQS-Adhoc: Wacker Neuson Group publishes preliminary financial year 2025 figures

Les Echos

Published on 02/10/2026 at 18:24, 6 hours 54 minutes ago

Mersen: Number of shares and voting rights as of January 31, 2026
Published on 02/10/2026 at 18:24, 6 hours 54 minutes ago

Mersen : nombre d'actions et de droits de vote au 31 janvier 2026
Published on 02/10/2026 at 18:00, 7 hours 18 minutes ago

CIS remporte plusieurs contrats stratégiques en Afrique, en Amérique du Sud et en Asie
Published on 02/10/2026 at 18:00, 7 hours 18 minutes ago

CIS wins several strategic contracts in Africa, South America and Asia
Published on 02/10/2026 at 17:45, 7 hours 33 minutes ago

Haulotte - 2025 Annual Sales

View all LES ECHOS COMFI WIRE